Silo Pharma financials
$1.61−2.42%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $18.0K | $18.0K | $18.0K | $18.0K | $18.0K | $18.0K | $18.0K | $18.0K | $18.0K | $18.0K | $18.0K |
| Gross profit | $0.00 | -$2.7K | -$2.7K | -$2.7K | $16.6K | $16.6K | $16.6K | $16.6K | $16.6K | $16.6K | $16.6K | $16.6K |
| Gross margin | — | −14.8% | −14.8% | −14.8% | 91.9% | 91.9% | 91.9% | 91.9% | 91.9% | 91.9% | 91.9% | 91.9% |
| Operating income | -$928.9K | -$1.6M | -$786.5K | -$1.2M | -$1.2M | -$1.1M | -$1.8M | -$1.0M | -$1.0M | -$879.5K | -$1.2M | -$773.4K |
| Net income | -$832.8K | -$1.6M | -$881.5K | -$1.1M | -$1.2M | -$1.0M | -$1.7M | -$928.8K | -$931.8K | -$801.7K | -$1.1M | -$660.2K |
| Net margin | — | −9137.5% | −4890.3% | −6160.5% | −6681.2% | −5721.9% | −9600.7% | −5152.9% | −5169.4% | −4447.3% | −6219.8% | −3662.5% |
| Diluted EPS | $-0.76 | $-0.12 | $-0.05 | $-0.12 | $-2.88 | $-0.23 | $-0.38 | $-0.22 | $-0.31 | $-0.28 | $-0.39 | $-0.21 |
| EBITDA | -$931.9K | -$1.6M | -$783.6K | -$1.1M | -$1.3M | -$1.1M | -$1.8M | -$1.0M | -$1.0M | -$879.5K | -$1.1M | -$773.4K |
| Operating cash flow | -$781.9K | -$822.6K | -$780.3K | -$955.5K | -$1.3M | -$1.6M | -$917.4K | -$1.3M | -$731.8K | -$838.2K | -$910.0K | -$1.6M |
| Free cash flow | -$827.0K | -$822.6K | -$780.3K | -$955.5K | -$1.3M | -$1.6M | -$917.4K | -$1.3M | -$731.8K | -$838.2K | -$910.0K | -$1.6M |
| Diluted shares | 1.1M | 13.7M | 19.3M | 9.3M | 0.4M | 4.5M | 4.5M | 4.3M | 3.1M | 2.9M | 2.9M | 3.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.3M | $3.9M | $4.7M | $3.9M | $4.3M | $3.1M |
| Short-term investments | $2.0M | $2.1M | $2.1M | $1.9M | $1.9M | $2.3M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $6.0M | $7.0M | $7.6M | $6.4M | $6.7M | $5.9M |
| Total liabilities | $1.1M | $1.3M | $1.3M | $1.4M | $1.7M | $1.9M |
| Shareholders' equity | $4.9M | $5.7M | $6.3M | $5.0M | $4.9M | $4.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology